Subscription Required

Only paid subscribers to Radar on Drug Benefits can access this Web portal with three years of back issues, searchable article archives and other valuable resources.

Subscribers to Radar on Drug Benefits receive

  • 24 biweekly issues of business strategies and analysis for health plans, employers, PBMs and pharmaceutical companies, delivered by First Class U.S. Mail and electronically,
  • Access to a subscriber-only Web page with:
    • Searchable archives of past articles,
    • Convenient library with PDFs of back issues,
    • Recent stories of interest grouped for convenient reading, and
    • Regular postings from your editor.
View a sample and get more information
November 8, 2018

Recent Stories

From Radar on Drug Benefits - CVS Health Corp. — which is on the brink of closing its $69 billion purchase of Aetna Inc. — is offering up more details about the “revolutionary” new health care model it plans to create after the companies officially combine. The Dept. of Justice approved the CVS-Aetna deal in mid-October, contingent upon Aetna selling its Medicare Part D Prescription Drug Plan (PDP) business to WellCare Health Plans, Inc. (RDB 10/11/18, p. 4). Read more

When a highly potent new opioid formulation was approved by his agency… Read more

When the Trump administration last month unveiled a proposal to revamp the… Read more

Researchers from Prime Therapeutics LLC recently presented studies on two approaches to… Read more

From the Editor

Welcome to Your Radar on Drug Benefits Subscriber Website

Exclusively for subscribers to Radar on Drug Benefits (formerly Drug Benefit News), this website is your source for PDFs of back issues, archives of articles and data, and more!

Please e-mail me with comments on the latest issue, story ideas for future issues or any other suggestions you have that can make the newsletter more useful for you.

January 10, 2018
Drug Benefit News is about to become Radar on Drug Benefits

With the Feb. 9, 2018, issue of DBN, we will adopt a new publication name: Radar on Drug Benefits. While our focus is still squarely on covering business strategies and analysis for health plans, employers, PBMs and pharma companies, our new name signals a renewed commitment to in-depth, forward-looking coverage. Every issue will bring incisive coverage of the companies, people, catalysts and trends that shape the drug benefits industry today and in the future.

Radar on Drug Benefits will join our other newly named publications: Radar on Medicare Advantage (formerly Medicare Advantage News) and Radar on Specialty Pharmacy (formerly Specialty Pharmacy News), available alongside Health Plan Weekly and Health Business Daily. Visit the AISHealth Marketplace for more information about our publications.

November 16, 2017
FDA Begins Implementing Naming Guidance

The FDA has started adding 4-letter suffixes to non-biosimilar biologics per its January final guidance: Mepsevii (vestronidase alfa-vjbk) and Hemlibra (emicizumab-kxwh)

September 28, 2017
Health Affairs urges PBMs to adopt stricter opioid edits on opt-out basis

In a recent blog posting, Health Affairs urged PBMs to start making opioid utilization management edits in accordance with CDC recommendations a standard feature in formulary management, so that plan sponsors must opt out if they do not want the feature in benefit plans, rather than requiring employers to opt in in order to get stricter opioid edits. View the post at http://healthaffairs.org/blog/2017/09/21/pharmacy-benefit-management/.